SynDevRx has developed a technology that increases the activity and safety of small molecule drugs using a conjugation technique. The company's technology increases a drug's therapeutic index by concentrating activity at the disease site. It provides small molecules with predictable and reliable physical properties that can speed up development time and lower costs while improving the PK profile. SynDevRx's lead drug candidate SDX-7320 targets the oncology market and inhibits MetAP2 - an enzyme that independent research has shown to be key to tumor growth, proliferation, and metastasis. The company was founded in 2007 and is based in Cambridge, Massachusetts.
SynDevRx has filed 24 patents.
Clusters of differentiation, Transcription factors, Diabetes, Immune system, Immunology
Clusters of differentiation, Transcription factors, Diabetes, Immune system, Immunology
Latest SynDevRx News
Sep 6, 2023
News provided by Share this article Share toX The dynamics of the triple-negative breast cancer market is anticipated to change in the coming years owing to the improvement in the diagnosis methodologies, rising awareness of the disease, incremental healthcare spending across the world, and the expected launch of emerging therapies during the forecast period LAS VEGAS, Sept. 6, 2023 /PRNewswire/ -- DelveInsight's Triple-Negative Breast Cancer Market Insights report includes a comprehensive understanding of current treatment practices, triple-negative breast cancer emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM [the United States, the EU-4 (Italy, Spain, France, and Germany), the United Kingdom, and Japan]. Key Takeaways from the Triple-Negative Breast Cancer Market Report As per DelveInsight analysis, the triple-negative breast cancer market size in the 7MM was ~USD 1.5 billion in 2022 and it is expected to grow positively at a significant CAGR during the study period (2019–2032). As per DelveInsight analysts, in the United States, there were around 40K cases of TNBC in 2022. Leading triple-negative breast cancer companies such as HiberCell, Hoffmann-La Roche, Infinity Pharmaceuticals, CytoDyn, Medicenna Therapeutics, Eli Lilly and Company, Tesaro, Inc., Merck Sharp & Dohme LLC, Gilead Sciences, NBE-Therapeutics AG, Daiichi Sankyo, Inc., Bristol-Myers Squibb, Celgene Corporation, Genentech, Inc., SynDevRx, Inc., GlaxoSmithKline, AstraZeneca, BioEclipse Therapeutics, Precigen, Inc, Clovis Oncology, Inc., Takeda, ModernaTX, Inc., Arcus Biosciences, Inc., Rapa Therapeutics LLC, BeiGene, OncXerna Theraputics, Inc., Jacobio Pharmaceuticals Co., Ltd., Novartis Pharmaceuticals, Astex Pharmaceuticals, Inc., A&G Pharmaceutical Inc., Zenith Epigenetics, Ayala Pharmaceuticals, Inc., Phoenix Molecular Designs, Celldex Therapeutics, CytomX Therapeutics, Exelixis, BioAtla, Inc., Sellas Life Sciences Group, AbbVie, BioNTech SE, Mundipharma Research Limited, NeoImmuneTech, Sanofi, Kymab Limited, and others are developing novel triple-negative breast cancer drugs that can be available in the triple-negative breast cancer market in the coming years. Some key therapies for triple-negative breast cancer treatment include Imprime PGG , TECENTRIQ, IPI-549, Leronlimab (PRO 140), MDNA11, LY3023414, Niraparib, Pembrolizumab, Sacituzumab Govitecan, NBE-002, L-NMMA, ASTX727, AG-01, ZEN003694, AL101, PMD-026, CDX-1140, and others. In December 2022, Vincerx Pharma announced that the US FDA has provided a safe to proceed letter and cleared the IND application for VIP236, the Company's front-runner SMDC for the treatment of advanced solid tumors. The Phase I trial hasstarted in January 2023, and currently it is in Recruiting stage. In November 2022, Infinity Pharmaceuticals provided the updatefrom its MARIO-3 study of eganelisib in combination withatezolizumab and nab-paclitaxel in front-line metastatic TNBC patients. In June 2022, Genexine reported the encouraging top-line results of the Phase Ib/II clinical trial with GX-I7 (efineptakin alfa) in R/RmTNBC. The observed ORRs were 15.7% for Phase Ib and 21.2% for Phase II. The company has also mentioned the expected market launchof drug in 2026 ~ with Partnership. Discover which therapies are expected to grab the major triple-negative breast cancer market share @ Triple-Negative Breast Cancer Market Report Triple-Negative Breast Cancer Overview Triple-negative breast cancer (TNBC) is a subtype of breast cancer characterized by the absence of three key receptors: estrogen receptors (ER), progesterone receptors (PR), and human epidermal growth factor receptor 2 (HER2). These receptors play a crucial role in regulating the growth of normal breast cells, and their absence in TNBC makes it more challenging to treat compared to other breast cancer types. The exact causes of triple-negative breast cancer are not fully understood, but certain risk factors have been identified. Genetic mutations, especially in the BRCA1 gene, are strongly associated with an increased risk of developing TNBC. Additionally, family history, early age at first menstruation, late age at menopause, obesity, and certain racial/ethnic backgrounds are also believed to influence the risk. Symptoms of TNBC are similar to other types of breast cancer and may include the presence of a lump in the breast or underarm, breast pain, changes in breast size or shape, skin changes on the breast, and nipple discharge other than breast milk. However, these symptoms are not exclusive to TNBC and can occur in other conditions as well. Diagnosing triple-negative breast cancer involves a combination of methods. Mammograms, ultrasounds, and MRI scans are common imaging techniques used to identify abnormalities in the breast tissue. Triple-Negative Breast Cancer Epidemiology Segmentation The triple-negative breast cancer epidemiology section provides insights into the historical and current triple-negative breast cancer patient pool and forecasted trends for individual seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The triple-negative breast cancer market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into: Total TNBC Incident Cases Triple-Negative Breast Cancer Treatment Market Triple-negative breast cancer (TNBC) presents a formidable challenge in oncology due to its unique characteristics. Lacking the three key receptors that are typically targeted in breast cancer treatment, TNBC requires a distinct therapeutic approach. The first line of treatment usually involves chemotherapy to curb its aggressive growth. Subsequently, surgical intervention is employed, often followed by radiation therapy to eliminate any remaining cancer cells. The absence of hormone receptors and HER2 amplification limits the effectiveness of hormone therapies and targeted treatments like Herceptin. However, recent advancements in the understanding of TNBC's molecular and genetic underpinnings have led to the exploration of new treatment avenues. Immune checkpoint inhibitors, such as pembrolizumab, have shown promise by unleashing the body's immune system against cancer cells. Additionally, research is uncovering potential targetable molecular pathways within TNBC cells. Personalized medicine is gaining traction, tailoring treatment plans based on the genetic makeup of individual tumors. Clinical trials are actively investigating combinations of therapies, including chemotherapy and immunotherapy, to enhance treatment responses. Early diagnosis through vigilant screening remains crucial, as TNBC is often diagnosed at more advanced stages. The evolving landscape of TNBC treatment underscores the necessity for multidisciplinary collaboration and continuous research to improve outcomes for those affected by this challenging breast cancer subtype. Key Triple-Negative Breast Cancer Therapies and Companies Imprime PGG : HiberCell Triple-Negative Breast Cancer Market Dynamics The triple-negative breast cancer market dynamics are marked by a complex interplay of challenges and opportunities. As a subtype of breast cancer characterized by the absence of estrogen receptor, progesterone receptor, and HER2 protein expression, TNBC poses a unique set of obstacles due to the lack of targeted therapies commonly effective in other breast cancer types. This has prompted extensive research efforts, leading to a surge in clinical trials exploring various treatment modalities such as immune checkpoint inhibitors, PARP inhibitors, and targeted therapies aimed at specific genetic mutations. The TNBC market has witnessed a significant collaboration between pharmaceutical companies, research institutions, and advocacy groups, all driven by a shared goal of advancing understanding and treatment options for this aggressive cancer type. This collaborative approach has not only accelerated drug discovery but has also facilitated the development of predictive biomarkers to identify potential responders to emerging therapies. Moreover, the growing emphasis on patient-centered care has led to increased awareness campaigns, support networks, and a demand for more accessible and affordable treatment options. While the absence of established targeted therapies initially presented hurdles, the evolving landscape of precision medicine and immunotherapy holds promise for improved outcomes in TNBC. However, these advancements also highlight the need for personalized treatment strategies, underscoring the complex interplay of genetic factors, immune responses, and the tumor microenvironment in TNBC patients. The TNBC market dynamics, therefore, reflect an intricate tapestry of scientific progress, clinical challenges, regulatory considerations, and patient advocacy, all converging to reshape the landscape of TNBC treatment and care. Report Metrics Triple-Negative Breast Cancer Market Size in 2022 USD 1.5 Billion Key Triple-Negative Breast Cancer Companies HiberCell, Hoffmann-La Roche, Infinity Pharmaceuticals, CytoDyn, Medicenna Therapeutics, Eli Lilly and Company, Tesaro, Inc., Merck Sharp & Dohme LLC, Gilead Sciences, NBE-Therapeutics AG, Daiichi Sankyo, Inc., Bristol-Myers Squibb, Celgene Corporation, Genentech, Inc., SynDevRx, Inc., GlaxoSmithKline, AstraZeneca, BioEclipse Therapeutics, Precigen, Inc, Clovis Oncology, Inc., Takeda, ModernaTX, Inc., Arcus Biosciences, Inc., Rapa Therapeutics LLC, BeiGene, OncXerna Theraputics, Inc., Jacobio Pharmaceuticals Co., Ltd., Novartis Pharmaceuticals, Astex Pharmaceuticals, Inc., A&G Pharmaceutical Inc., Zenith Epigenetics, Ayala Pharmaceuticals, Inc., Phoenix Molecular Designs, Celldex Therapeutics, CytomX Therapeutics, Exelixis, BioAtla, Inc., Sellas Life Sciences Group, AbbVie, BioNTech SE, Mundipharma Research Limited, NeoImmuneTech, Sanofi, Kymab Limited, and others Key Triple-Negative Breast Cancer Therapies Imprime PGG , TECENTRIQ, IPI-549, Leronlimab (PRO 140), MDNA11, LY3023414, Niraparib, Pembrolizumab, Sacituzumab Govitecan, NBE-002, L-NMMA, ASTX727, AG-01, ZEN003694, AL101, PMD-026, CDX-1140, and others Scope of the Triple-Negative Breast Cancer Market Report Therapeutic Assessment: Triple-Negative Breast Cancer current marketed and emerging therapies Triple-Negative Breast Cancer Market Dynamics: Conjoint Analysis of Emerging Triple-Negative Breast Cancer Drugs Competitive Intelligence Analysis: SWOT analysis and Market entry strategies Unmet Needs, KOL's views, Analyst's views, Triple-Negative Breast Cancer Market Access and Reimbursement Table of Contents Triple-Negative Breast Cancer Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key Triple-Negative Breast Cancer companies, including Shanghai Henlius Biotech, Jiangsu HengRui Medicine Co., Ltd., G1 Therapeutics, Inc., Infinity Pharmaceuticals, HiberCell, Inc., Zenith Epigenetics, BioLite, Inc., Abbisko Therapeutics, Phoenix Molecular Designs, OncoTherapy Science, ModernaTX, Inc, NuGenerex Immuno-Oncology, Pfizer, Jiangsu Alphamab Biopharmaceuticals Co., Ltd., BioLite, Inc., ImmunityBio, Inc., PharmAbcine, Genexine, Inc., CSPC ZhongQi Pharmaceutical Technology Co., Ltd., Novartis Pharmaceuticals, Klus Pharma, Ayala Pharmaceuticals, Inc, Akeso Biopharma, Chipscreen Biosciences, OncoPep, Inc., Iovance Biotherapeutics, Inc., SynDevRx, Inc., Hoffmann-La Roche, Celcuity, Inc., Amgen, AstraZeneca, NBE-Therapeutics AG, Fusion Pharmaceuticals, Immutep Limited, among others.
SynDevRx Frequently Asked Questions (FAQ)
When was SynDevRx founded?
SynDevRx was founded in 2007.
Where is SynDevRx's headquarters?
SynDevRx's headquarters is located at One Broadway, Cambridge.
What is SynDevRx's latest funding round?
SynDevRx's latest funding round is Debt - III.
How much did SynDevRx raise?
SynDevRx raised a total of $38.38M.
Who are SynDevRx's competitors?
Competitors of SynDevRx include BioDelivery Sciences International, Amplyx Pharmaceuticals, Ra Pharmaceuticals, The Medicines Company, Milestone Pharmaceuticals and 11 more.
Compare SynDevRx to Competitors
Konova offers anti-obesity drug development
Solidus Biosciences is a company that received a STTR Phase II grant for a project entitled: Development of a Lead Optimization Chip for Drug Discovery. Their award is funded under the American Recovery and Reinvestment Act of 2009 and their project will address further development and commercialization of a multi-enzyme lead optimization chip (Multizyme Chip) for high-throughput generation of lead compound analogs coupled with cell-based screening for the rapid identification of biologically active derivatives. Such a capability directly impacts a key bottleneck in drug discovery; namely, the efficient optimization of lead compounds to develop drugs with optimal pharmacological properties. Solidus Biosciences, Inc. proposes to combine six biocatalysis with pharmacological screening to provide rapid identification of biologically active compounds against cell-specific targets, which is a new paradigm for lead optimization. Moreover, the Multizyme Chip platform will be well-suited for lead optimization in related industries, including agrochemicals, cosmetics, and cosmeceuticals. The Solidus technology will thus improve the competitiveness and efficiency of the pharmaceutical, cosmetics, and chemical industries, and will serve as a rich source of new and improved commercial products. The broader impacts of this research are the advances that Solidus Biosciences will achieve toward generating better and safer drugs, reducing the cost to develop these drugs, and increasing the overall efficiency of the pharmaceutical industry. Solidus will generate Multizyme Chips for purchase by pharmaceutical and biotechnology companies to facilitate their lead optimization programs, particularly those involving natural product-derived and complex synthetic small molecule leads. Cryopreservation techniques developed in Phase II will enable the sale of chips and chip-handling devices produced during Phase I, and will allow seamless penetration of the Solidus technology platform into the company's target markets. Solidus Biosciences is a company that received a STTR Phase I grant for a project entitled: Development of a Lead Optimization Chip for Drug Discovery. Their research project aims to develop a new method for generating lead compounds by using enzymatic modification of compound sets. Availability of new methodology to generate biologically active compounds from existing molecules may enhance the success of the drug discovery process and may lead to the discovery of new and useful therapeutics. Solidus Biosciences is a company that received a STTR Phase I grant for a project entitled: High-Throughput RNAi Screening of Mammalian Cells. Their research project aims to develop a system for the rapid screening of siRNAs that can inhibit genes involved in cellular responses such as hyperosmotic stress that can affect pathways of high commercial importance, including protein production. Use of hyperosmotic stress as a proof of concept system will demonstrate the feasibility of high-throughput RNAi screening and will at the same time yield results that can be used to improve monoclonal antibody production in commercial and laboratory settings Production of biopharmaceuticals such as antibodies is exquisitely responsive to the culture conditions under which the cells are grown and thus can be improved through optimizing such settings, which in turn, would affect the genes involved in the specific synthetic pathways of interest. Development of a rapid methodology to identify inhibitory RNA molecules that can inhibit genes that adversely affect yield would be of significant importance to pharmaceutical companies that produce protein therapeutics and may result in a lowering of the const of these therapeutic entities.
Auxeris Therapeutics, Inc. is engaged in osteoporosis drug development
Paloma Pharmaceuticals, Inc. is a drug development company focusing on pathologies with a vascular component including cancer, ocular diseases (macular degeneration and diabetic retinopathy), arthritis, fibrotic diseases (pulmonary fibrosis) endometriosis, osteoporosis and skin diseases (psoriasis and atopic dermatitis). Paloma owns the intellectual property relating to a series of , small molecule drugs created through an integrated design platform incorporating , customized and industry standard computational tools that has therapeutic potential for the treatment of the foregoing diseases.
RegeneMed, Inc. is accelerating the development of safer, more effective drugs by providing integrated high throughput platforms incorporating engineered human tissue-based assays. RegeneMed possesses patented, proprietary, core technologies enabling the in vitro growth of engineered human tissues, including liver, GI tract, bone marrow and blood-brain barrier. These tissue-based in vitro model systems will accelerate drug development and aims to debottleneck ADME/Tox evaluation, the leading cause of drug failures facing the pharmaceutical industry, per the company.
Salzburg Therapeutics is a drug development company that is developing Cytotoxamer and Genotoxamer products for cancer treatment. The company's technology aims to provide a solution for delivering activated forms of anticancer drugs, nanoparticles, and other moieties specifically to cancer cells.